NervGen Launches Underwritten Common Share and Warrant Offering for NVG-291 Financing
NervGen has launched an underwritten public offering of common shares, pre-funded warrants and warrants under its December 2025 Base Shelf Prospectus and effective Form F-10 registration. Net proceeds will fund advancement of NVG-291 through clinical studies and support general corporate and working capital needs.
1. Offering Structure
NervGen has commenced an underwritten public offering comprising common shares, pre-funded warrants and accompanying warrants to purchase common shares. The offering is made under its amended and restated short form base shelf prospectus dated December 15, 2025 and its shelf registration on Form F-10 effective January 7, 2026, and remains subject to customary closing conditions.
2. Underwriters and Filings
Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering. A prospectus supplement will be filed with Canadian regulators and the SEC and will be accessible on SEDAR+ and EDGAR within two business days.
3. Use of Proceeds
NervGen intends to use net proceeds from the offering, together with its existing cash and cash equivalents, to advance its lead drug candidate NVG-291 through clinical trials and to fund general corporate and working capital purposes.